209747-05-7

Basic information

• Product Name: Tolterodin hydrogen tartrate
• Synonyms: Tolterodin hydrogen tartrate;Tolterodin tartrate;(R)-Tolterodine L-tartrate
• CAS NO: 209747-05-7
• Molecular Formula: C26H37NO7
• Molecular Weight: 475.57448
• Mol File: 209747-05-7.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 442.2 °C at 760 mmHg
• Flash Point: 192.1 °C
• Appearance: /
• CAS DataBase Reference: Tolterodin hydrogen tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Tolterodin hydrogen tartrate(209747-05-7)
• EPA Substance Registry System: Tolterodin hydrogen tartrate(209747-05-7)

Safety Data

• Hazardous Substances Data: 209747-05-7(Hazardous Substances Data)

Usage

General Description

Tolterodine hydrogen tartrate is a chemical compound used as an active ingredient in medications to treat overactive bladder. It works by relaxing the muscles of the bladder, reducing the urge to urinate frequently and the incidents of incontinence. Tolterodine hydrogen tartrate is part of a class of drugs known as antimuscarinics, which block certain nerve signals in the body that are responsible for causing overactive bladder symptoms. It is available in oral tablet and extended-release capsule forms and is usually taken once or twice daily, as prescribed by a healthcare professional. Common side effects of tolterodine hydrogen tartrate include dry mouth, constipation, and headache. It is important to follow the dosage and usage instructions provided by a doctor to ensure safe and effective treatment.

Upstream product

• 138508-61-9 L-tartaric acid 
• 837376-36-0 3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-aminium bromide 
• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 147-71-7 D-tartaric acid 
• 87-69-4 L-Tartaric acid 
• 897314-72-6 (+/-)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propanamide 
• 1043911-42-7 N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propylamine L-tartrate 
• 854306-67-5 methyl 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropionate 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 
• 389068-22-8 N,N-diisopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropylamine 
• 854306-68-6 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol 
• 828933-86-4 (4R)-6-methyl-4-phenylchroman-2-ol 
• 108-18-9 diisopropylamine 
• 827007-19-2 (R)-6-methyl-4-phenyl-3,4-dihydrochromen-2-one 

Downstream Products

• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 214601-54-4 (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal 
• 156755-37-2 {4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]phenyl}methanol 
• 848768-06-9 (R)-3-[2-(benzyloxy)-5-methylphenyl]-N,N-diisopropyl-3-phenylpropan-1-amine 
• 380636-50-0 (R)-5-hydroxymethyl tolterodine fumarate salt 

Relevant articles and documents

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

Chiral separation of tolterodine tartrate using amylosed base immobilized stationary phase in LC method

High-performance liquid chromatographic method was developed and validated for chiral separation of tolterodine tartrate. It was achieved on Chiral pack IA (immobilized amylosed based polysaccharides stationary phase) using a mobile phase of hexane: 2-propanol: triethylamine: trifluroacetic acid (91:9:0.2:0.1 v/v) at a flow rate 1.1 mL/min. Resolution between S-tolterodine tartrate and R-tolterodine tartrate was found to be 2.9. Developed LC method was used for the quantification of S-tolterodine tartrate as chiral impurity in Rtolterodine tartrate. The developed method was extensively validated and proved to be robust. The calibration curve for S-tolterodine tartrate showed an excellent linearity over the concentrations range 0.1 to 10 μg/mL. The limit of detection and limit of quantification for S-tolterodine tartrate were 0.11 μg/mL and 0.34 μg/mL respectively. Average recovery of S-isomer was in the range of 97.30 to 101.59 %. S-tolterodine tartrate and R-tolterodine tartrate solutions in mobile phase were found to be stable for 48 h. The proposed method was short runtime, precise and accurate for quantitative determination of S-isomer in R-tolterodine tartrate in API and its solid oral dosage form.

Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate

The invention concerns an improved process for the preparation of tolterodine (N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propylamine) and its salts, in particular for the preparation of the tartrate salt, and more in particular for the (+)-(R) enantiomer of tolterodine L-tartrate, starting from a novel intermediate, N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-2-propenamide which can be used as pure Z or E isomer or as a mixture of Z and E isomers.